Ischämische komplikationen in der neurochirurgie: Einsatz von kalziumantagonisten

Translated title of the contribution: Ischemic complications in neurosurgery: Use of calcium antagonists

Matthias Merkel, Ansgar Brambrink

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Dysregulation of the intracellular calcium concentration is thought to play a key role in the so-called ischemic cascade, as well as for the development of cerebral vasospasm after subarachnoid haemorrhaging (SAH). Therefore, the prophylactic/therapeutic administration of cerebral calcium channel blockers for neurosurgical patients appears to be a compelling idea to prevent ischemic complications. There are abundant data on the efficacy of cerebral calcium antagonists in various animal models of central nervous system pathologies, however, very little clinical evidence exists to justify their use in humans in respective situations. So far there is only evidence for a long-term treatment effect of oral nimodipine in patients suffering from SAH, and this is based essentially on one large controlled clinical trial. Experimental results suggest that blockers of other calcium channel subtypes may be promising for future clinical roles in primary or secondary ischemic brain injury. However, it is also possible that calcium-independent mechanisms play a more important role during the development of the ischemic damage than previously assumed. Currently, there is no clinical evidence to support the prophylactic use of calcium antagonists to prevent ischemic complications in neurosurgical patients without SAH.

Original languageGerman
Pages (from-to)794-802
Number of pages9
JournalAnaesthesist
Volume57
Issue number8
DOIs
StatePublished - Aug 2008

Fingerprint

Neurosurgery
Calcium
Calcium Channel Blockers
Intracranial Vasospasm
Nimodipine
Controlled Clinical Trials
Brain Injuries
Central Nervous System
Animal Models
Pathology
Therapeutics

Keywords

  • Calcium antagonist
  • Calcium channel blocker
  • Cerebral vasospasm
  • Ischemic complications
  • Magnesium sulfate
  • Nimodipine

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Ischämische komplikationen in der neurochirurgie : Einsatz von kalziumantagonisten. / Merkel, Matthias; Brambrink, Ansgar.

In: Anaesthesist, Vol. 57, No. 8, 08.2008, p. 794-802.

Research output: Contribution to journalArticle

@article{4641749cc04848349d7699f29d4b31b6,
title = "Isch{\"a}mische komplikationen in der neurochirurgie: Einsatz von kalziumantagonisten",
abstract = "Dysregulation of the intracellular calcium concentration is thought to play a key role in the so-called ischemic cascade, as well as for the development of cerebral vasospasm after subarachnoid haemorrhaging (SAH). Therefore, the prophylactic/therapeutic administration of cerebral calcium channel blockers for neurosurgical patients appears to be a compelling idea to prevent ischemic complications. There are abundant data on the efficacy of cerebral calcium antagonists in various animal models of central nervous system pathologies, however, very little clinical evidence exists to justify their use in humans in respective situations. So far there is only evidence for a long-term treatment effect of oral nimodipine in patients suffering from SAH, and this is based essentially on one large controlled clinical trial. Experimental results suggest that blockers of other calcium channel subtypes may be promising for future clinical roles in primary or secondary ischemic brain injury. However, it is also possible that calcium-independent mechanisms play a more important role during the development of the ischemic damage than previously assumed. Currently, there is no clinical evidence to support the prophylactic use of calcium antagonists to prevent ischemic complications in neurosurgical patients without SAH.",
keywords = "Calcium antagonist, Calcium channel blocker, Cerebral vasospasm, Ischemic complications, Magnesium sulfate, Nimodipine",
author = "Matthias Merkel and Ansgar Brambrink",
year = "2008",
month = "8",
doi = "10.1007/s00101-008-1394-y",
language = "German",
volume = "57",
pages = "794--802",
journal = "Der Anaesthesist",
issn = "0003-2417",
publisher = "Springer Verlag",
number = "8",

}

TY - JOUR

T1 - Ischämische komplikationen in der neurochirurgie

T2 - Einsatz von kalziumantagonisten

AU - Merkel, Matthias

AU - Brambrink, Ansgar

PY - 2008/8

Y1 - 2008/8

N2 - Dysregulation of the intracellular calcium concentration is thought to play a key role in the so-called ischemic cascade, as well as for the development of cerebral vasospasm after subarachnoid haemorrhaging (SAH). Therefore, the prophylactic/therapeutic administration of cerebral calcium channel blockers for neurosurgical patients appears to be a compelling idea to prevent ischemic complications. There are abundant data on the efficacy of cerebral calcium antagonists in various animal models of central nervous system pathologies, however, very little clinical evidence exists to justify their use in humans in respective situations. So far there is only evidence for a long-term treatment effect of oral nimodipine in patients suffering from SAH, and this is based essentially on one large controlled clinical trial. Experimental results suggest that blockers of other calcium channel subtypes may be promising for future clinical roles in primary or secondary ischemic brain injury. However, it is also possible that calcium-independent mechanisms play a more important role during the development of the ischemic damage than previously assumed. Currently, there is no clinical evidence to support the prophylactic use of calcium antagonists to prevent ischemic complications in neurosurgical patients without SAH.

AB - Dysregulation of the intracellular calcium concentration is thought to play a key role in the so-called ischemic cascade, as well as for the development of cerebral vasospasm after subarachnoid haemorrhaging (SAH). Therefore, the prophylactic/therapeutic administration of cerebral calcium channel blockers for neurosurgical patients appears to be a compelling idea to prevent ischemic complications. There are abundant data on the efficacy of cerebral calcium antagonists in various animal models of central nervous system pathologies, however, very little clinical evidence exists to justify their use in humans in respective situations. So far there is only evidence for a long-term treatment effect of oral nimodipine in patients suffering from SAH, and this is based essentially on one large controlled clinical trial. Experimental results suggest that blockers of other calcium channel subtypes may be promising for future clinical roles in primary or secondary ischemic brain injury. However, it is also possible that calcium-independent mechanisms play a more important role during the development of the ischemic damage than previously assumed. Currently, there is no clinical evidence to support the prophylactic use of calcium antagonists to prevent ischemic complications in neurosurgical patients without SAH.

KW - Calcium antagonist

KW - Calcium channel blocker

KW - Cerebral vasospasm

KW - Ischemic complications

KW - Magnesium sulfate

KW - Nimodipine

UR - http://www.scopus.com/inward/record.url?scp=49749108563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49749108563&partnerID=8YFLogxK

U2 - 10.1007/s00101-008-1394-y

DO - 10.1007/s00101-008-1394-y

M3 - Article

C2 - 18551259

AN - SCOPUS:49749108563

VL - 57

SP - 794

EP - 802

JO - Der Anaesthesist

JF - Der Anaesthesist

SN - 0003-2417

IS - 8

ER -